Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study

    Clinical therapeutics, Volume 33, Issue 3, 2011, Pages 315-327.

    Cited by: 31|Bibtex|Views3|Links
    WOS SCOPUS
    Keywords:
    pharmacokineticsvandetanibcancerchinese patientstolerabilityMore(2+)

    Abstract:

    Vandetanib (ZD6474) is an orally available inhibitor of 3 signaling pathways important in tumor progression: vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection tyrosine kinase activity. Current development of vandetanib is focused on the treatment of non-small-cell lung cancer...More

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments